U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2Cl.Pt.2H3N
Molecular Weight 300.051
Optical Activity NONE
Additional Stereochemistry Yes
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0
Stereo Comments SP-4-1 (TRANS)

SHOW SMILES / InChI
Structure of TRANSPLATIN

SMILES

N.N.[Cl-].[Cl-].[Pt++]

InChI

InChIKey=LXZZYRPGZAFOLE-UHFFFAOYSA-L
InChI=1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2

HIDE SMILES / InChI
Molecular Formula Cl
Molecular Weight 35.453
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula H3N
Molecular Weight 17.0305
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula Pt
Molecular Weight 195.084
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.drugbank.ca/drugs/DB00515 | https://www.ncbi.nlm.nih.gov/pubmed/27736024 | https://www.ncbi.nlm.nih.gov/pubmed/25159039

There is no available sources on the medical use of platinum iodide. The salt is insoluble.

CNS Activity

CNS Non-penetrant
1014
Curator's Comment: With the injection of cisplatin into mice 3 h after the LPS treatment, platinum was detected in the CCR during the 7 days after the injection, while platinum was not detected in the CCR of cisplatin-injected mice without LPS pretreatment and of mice simultaneous treated with cisplatin and LPS.

Originator

Approval Year

1978
87
Targets

Targets

Primary TargetPharmacologyConditionPotency
DNA
278
Target ID: CHEMBL2311221
Crosslinking Agent
81
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
CISPLATIN

Approved Use

Cisplatin injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin injection and cyclophosphamide. Cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin injection therapy. Advanced Bladder Cancer Cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.

Launch Date

2.82873594E11
Primary
Approved
8429
CISPLATIN

Approved Use

Cisplatin injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin injection and cyclophosphamide. Cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin injection therapy. Advanced Bladder Cancer Cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.

Launch Date

2.82873594E11
Primary
Approved
8429
CISPLATIN

Approved Use

Cisplatin injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin injection and cyclophosphamide. Cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin injection therapy. Advanced Bladder Cancer Cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.

Launch Date

2.82873594E11
Primary
Phase IV
63
CISPLATIN

Approved Use

Cisplatin injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of Cisplatin injection and cyclophosphamide. Cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin injection therapy. Advanced Bladder Cancer Cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.

Launch Date

2.82873594E11
PubMed

PubMed

TitleDatePubMed
Platinum(II) chloride-catalyzed stereoselective domino enyne isomerization/Diels-Alder reaction.
2010 Nov 19
Platinum-catalyzed one-pot alkenylation of aldehydes using alkynes and triethylsilane: dual catalysis by platinum(II) chloride.
2013 Nov 1
Patents

Patents

WO2017059434
4

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 12:48:51 UTC 2023
Edited
by admin
on Sat Dec 16 12:48:51 UTC 2023
Record UNII
BW0OY6ZTD4
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TRANSPLATIN
Common Name English
TRANS-DIAMINEDICHLOROPLATINUM
Common Name English
TRANS-DDP
Common Name English
TRANS-DICHLORODIAMMINEPLATINUM(II)
Systematic Name English
CISPLATIN IMPURITY A [EP IMPURITY]
Common Name English
(SP-4-1)-DIAMMINEDICHLOROPLATINUM
Systematic Name English
TRANSPLATIN [USP-RS]
Common Name English
PLATINUM, DIAMMINEDICHLORO-, (SP-4-1)-
Systematic Name English
TRANS-DICHLORODIAMINEPLATINUM(II)
Systematic Name English
TRANS-PLATINUMDIAMMINE DICHLORIDE
Systematic Name English
NSC-131558
Code English
TRANS-PLATINUM(II) AMMONIUM CHLORIDE
Systematic Name English
TRANS-DIAMMINEDICHLOROPLATINUM(II)
Common Name English
TRANS-DICHLORODIAMMINE PLATINUM
Systematic Name English
TRANS-DIAMMINEDICHLOROPLATINUM
Common Name English
Code System Code Type Description
PUBCHEM
84691
Created by admin on Sat Dec 16 12:48:51 UTC 2023 , Edited by admin on Sat Dec 16 12:48:51 UTC 2023
PRIMARY
CAS
14913-33-8
Created by admin on Sat Dec 16 12:48:51 UTC 2023 , Edited by admin on Sat Dec 16 12:48:51 UTC 2023
PRIMARY
NSC
131558
Created by admin on Sat Dec 16 12:48:51 UTC 2023 , Edited by admin on Sat Dec 16 12:48:51 UTC 2023
PRIMARY
HSDB
3940
Created by admin on Sat Dec 16 12:48:51 UTC 2023 , Edited by admin on Sat Dec 16 12:48:51 UTC 2023
PRIMARY
FDA UNII
BW0OY6ZTD4
Created by admin on Sat Dec 16 12:48:51 UTC 2023 , Edited by admin on Sat Dec 16 12:48:51 UTC 2023
PRIMARY
CHEBI
35852
Created by admin on Sat Dec 16 12:48:51 UTC 2023 , Edited by admin on Sat Dec 16 12:48:51 UTC 2023
PRIMARY
EPA CompTox
DTXSID101016811
Created by admin on Sat Dec 16 12:48:51 UTC 2023 , Edited by admin on Sat Dec 16 12:48:51 UTC 2023
PRIMARY
RS_ITEM_NUM
1672803
Created by admin on Sat Dec 16 12:48:51 UTC 2023 , Edited by admin on Sat Dec 16 12:48:51 UTC 2023
PRIMARY
WIKIPEDIA
Transplatin
Created by admin on Sat Dec 16 12:48:51 UTC 2023 , Edited by admin on Sat Dec 16 12:48:51 UTC 2023
PRIMARY
ECHA (EC/EINECS)
238-980-9
Created by admin on Sat Dec 16 12:48:51 UTC 2023 , Edited by admin on Sat Dec 16 12:48:51 UTC 2023
PRIMARY
Related Record Type Details
Structure of CISPLATIN
PARENT -> IMPURITY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966